Physician profile
Beth A Bryant
NPI 1861436917
$6,785.91
in general payments reported to CMS, 2019-2025
33 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $474 · 2021: $1,009 · 2022: $1,163 · 2023: $1,246 · 2024: $1,166 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.48 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,047.18 | 2019-2025 | |
| Amgen INC. | $884.09 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $695.35 | 2019-2024 | Farxiga, Atacand, Brilinta |
| Pfizer INC. | $658.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $586.21 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.79 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $378.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $273.50 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $269.90 | 2021-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $251.78 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $184.90 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $175.40 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.28 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $162.18 | 2019-2025 | Bodyguardian, Watchman Access System, Cds - Mct/Cem Monitoring |
| Lexicon Pharmaceuticals, INC. | $90.03 | 2023-2024 | Inpefa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.91 | 2019-2021 | |
| Esperion Therapeutics, INC. | $64.69 | 2020-2024 | Nexletol |
| Abiomed | $37.66 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $33.12 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $32.23 | 2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $21.40 | 2025 | Injectafer |
| Stryker Corporation | $20.37 | 2025 | Flowtriever |
| Vital Connect, INC | $20.12 | 2023 | Vitalpatch Rtm |
| Chiesi USA, INC. | $19.96 | 2025 | Juxtapid |
| Medtronic, INC. | $17.28 | 2021 | |
| Ethicon US, LLC | $16.58 | 2025 | Ethicon, Surgicel Nu-Knit |
| Philips North America LLC | $14.39 | 2023 | |
| Lundbeck LLC | $14.26 | 2020 | |
| Scpharmaceuticals INC. | $14.14 | 2023 | |
| Inspire Medical Systems, INC. | $13.54 | 2024 | Inspire |
| Altathera Pharmaceuticals LLC | $12.99 | 2023 | Sotalol Hydrochloride |
| Bardy Diagnostics, INC. | $12.24 | 2020 | |
| Cvrx, INC. | $10.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.